Blockchain Registration Transaction Record

FamiCord's Bramble Bio to Manufacture VERIGRAFT's P-TEV for Phase II/III Trial

FamiCord's Bramble Bio signs with VERIGRAFT to manufacture P-TEV for Phase II/III trial in chronic venous insufficiency, boosting CDMO activities.

This partnership underscores the growing importance of specialized CDMO services in advancing personalized regenerative medicines. By securing manufacturing for P-TEV, VERIGRAFT moves closer to delivering a potentially curative treatment for severe chronic venous insufficiency, a condition affecting millions worldwide. For FamiCord, the deal validates its strategic expansion into high-value ATMP manufacturing and strengthens its position in the rapidly evolving cell and gene therapy market. Successful execution could accelerate patient access to innovative therapies and pave the way for similar collaborations.